Search
Clofazimine
go.drugbank.com/drugs/DB00845ApprovedInvestigationalWithdrawnIt was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. … [A203144] Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis
Afatinib
go.drugbank.com/drugs/DB08916ApprovedInvestigationalAfatinib is a 4-anilinoquinazoline tyrosine kinase inhibitor in the form of a dimaleate salt available as Boehringer Ingelheim's brand name Gilotrif [FDA Label]. … use, afatinib tablets are a first-line (initial) treatment for patients with metastatic non-small cell lung cancer (NSCLC) with common epidermal growth factor receptor (EGFR) mutations as detected by an
Moxifloxacin
go.drugbank.com/drugs/DB00218ApprovedInvestigationalBayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for oral treatment.
Products: MOXIFLOXACINA DOUBLE-E PHARMAAtomoxetine
go.drugbank.com/drugs/DB00289ApprovedInvestigational[A18262] This is beneficial in the treatment of ADHD as DA activation in the subcortical NA and striatum is associated with many stimulant-associated side effects and an increase in abuse potential, which … within prefrontal regions of the brain, which are involved in attention and memory.
Dydrogesterone
go.drugbank.com/drugs/DB00378ApprovedInvestigationalWithdrawnUnlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.
Anagrelide
go.drugbank.com/drugs/DB00261ApprovedInvestigational[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. … Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.
Anifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigational[A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929] … Anifrolumab, or MEDI-546, is a type 1 interferon receptor (IFNAR) inhibiting IgG1κ monoclonal antibody indicated in the treatment of adults with moderate to severe systemic lupus erythematosus.
Daclatasvir
go.drugbank.com/drugs/DB09102ApprovedInvestigationalWithdrawnThe same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. … The most common critical NS5A amino acid substitutions that led to reduced susceptibility to daclatasvir therapy occured at position Q30 (Q30H/K/R) and M28 in genotype 1a patients and Y93H in genotype
Haloperidol
go.drugbank.com/drugs/DB00502ApprovedInvestigational[A180625] The efficacy of haloperidol was first established in controlled trials in the 1960s.[A180610] … However, these findings contradict the findings from studies in vitro with human liver microsomes and from drug interaction studies in vivo.
Products: MYUNG IN HALOPERIDOL TABLET 1.5 mg, MYUNG IN HALOPERIDOL INJECTION 5 mg/mlAnsuvimab
go.drugbank.com/drugs/DB16385ApprovedInfection with pathogenic filoviruses, such as _Zaire ebolavirus_ (Ebola virus, EBOV), can cause severe hemorrhagic fever in humans, resulting in frequent outbreaks with case fatality rates as high as … [A225943, A225948, A226035] A randomized, controlled trial of four investigational therapies for Ebola virus disease (EVD) in the Democratic Republic of Congo during a previous outbreak that began in 2018